A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
This primary purpose of this study is to estimate the maximum tolerated dose (MTD) and/or
recommended dose for expansion (RDE) and preferred dosing schedule of LJM716 given by IV
infusion in adult patients with squamous cell carcinoma of head and neck, or esophagus, or
HER2 overexpressing metastatic breast cancer or gastric cancer